{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T09:57:24Z","timestamp":1753869444139,"version":"3.41.2"},"reference-count":40,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T00:00:00Z","timestamp":1742169600000},"content-version":"vor","delay-in-days":16,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["JGH Open"],"published-print":{"date-parts":[[2025,3]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:sec><jats:title>Introduction<\/jats:title><jats:p>Metabolic dysfunction\u2010associated steatohepatitis (MASH), an advanced form of fatty liver disease, is characterized by liver inflammation and fibrosis, with an emerging interest in fibroblast growth factor (FGF)\u201021 analogs, particularly pegbelfermin (PGBF). This study evaluates the efficacy and safety of PGBF in treating MASH\u2010associated hepatic fibrosis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This meta\u2010analysis followed Cochrane guidelines and PRISMA standards. A comprehensive search of databases up to January 2023 focused on randomized controlled trials (RCTs) comparing PGBF to placebo for MASH. Meta\u2010analyses were performed with RevMan 5.4 using a random\u2010effects model.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Data from 452 participants across three RCTs were analyzed. Significant improvements in adiponectin concentration were observed in both the 10\u2009mg [MD\u2009=\u200918.23, 95% CI (6.35, 30.11), <jats:italic>p<\/jats:italic>\u2009=\u20090.003] and 20\u2009mg [MD\u2009=\u200918.09, 95% CI (5.88, 30.31), <jats:italic>p<\/jats:italic>\u2009=\u20090.004] PGBF groups compared to placebo. Significant reductions in PRO\u2010C3 concentration were noted in both the 10\u2009mg [MD\u2009=\u2009\u221225.50, 95% CI (\u221243.95, \u22127.05), <jats:italic>p<\/jats:italic>\u2009=\u20090.007] and 20\u2009mg [MD\u2009=\u2009\u221219.54, 95% CI (\u221233.33, \u22125.76), <jats:italic>p<\/jats:italic>\u2009=\u20090.005] groups. Significant improvement in MASH was seen in the 10\u2009mg group [RR\u2009=\u20092.84, 95% CI (1.18, 6.78), <jats:italic>p<\/jats:italic>\u2009=\u20090.02] but not in the 20\u2009mg group. No significant improvements in liver stiffness, Modified Ishak scores, collagen proportionate area, ALT and AST levels, or treatment\u2010emergent adverse events (TEAEs) were observed in either dosage group.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Pegbelfermin, a promising therapy for MASH fibrosis, has demonstrated effectiveness at 10\u2009mg, significantly improving MASH and biomarkers including adiponectin and PRO\u2010C3, while maintaining a generally safe profile.<\/jats:p><\/jats:sec>","DOI":"10.1002\/jgh3.70131","type":"journal-article","created":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T06:37:16Z","timestamp":1742279836000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Evaluating the Effectiveness of Pegbelfermin in <scp>MASH<\/scp>\u2010Associated Hepatic Fibrosis A Meta\u2010Analysis and Systematic Review of Randomized Controlled Trials"],"prefix":"10.1002","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4010-7545","authenticated-orcid":false,"given":"Muhammad","family":"Shahzil","sequence":"first","affiliation":[{"name":"Department of Internal Medicine Penn State Health Milton S Hershey Medical Center  Hershey Pennsylvania USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fariha","family":"Hasan","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine Cooper University Hospital  Camden New Jersey USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Syeda Kanza","family":"Kazmi","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine Penn State Health Milton S Hershey Medical Center  Hershey Pennsylvania USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manesh Kumar","family":"Gangwani","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine The University of Toledo  Toledo Ohio USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"UmmeSalma","family":"Shabbar","sequence":"additional","affiliation":[{"name":"Dow Medical College  Karachi Pakistan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ammad Javaid","family":"Chaudhary","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine Henry Ford Hospital  Detroit Michigan USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-2863-8352","authenticated-orcid":false,"given":"Muhammad Ali","family":"Khaqan","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine John H. Stroger, Jr. Hospital of Cook County  Chicago Illinois USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammad Saad","family":"Faisal","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine Henry Ford Hospital  Detroit Michigan USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathy N.","family":"Williams","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology Cooper University Hospital  Camden New Jersey USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9512-8693","authenticated-orcid":false,"given":"Babu P.","family":"Mohan","sequence":"additional","affiliation":[{"name":"Gastroenterology and Hepatology Orlando Gastroenterology PA  Orlando Florida USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christina","family":"Tofani","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology Cooper University Hospital  Camden New Jersey USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2025,3,17]]},"reference":[{"volume-title":"Nonalcoholic Steatohepatitis (NASH)","year":"2023","author":"Sharma B.","key":"e_1_2_9_2_1"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.17995"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000000004"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(22)00165-0"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S315724"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.603926"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.3350\/cmh.2022.0365"},{"issue":"1","key":"e_1_2_9_9_1","first-page":"40","article-title":"Drugs for Non\u2010Alcoholic Steatohepatitis (NASH): Quest for the Holy Grail","volume":"9","author":"Sharma M.","year":"2021","journal-title":"Journal of Clinical and Translational Hepatology"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.2298"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00535-024-02122-x"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00535-024-02158-z"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1097\/MOL.0000000000000599"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41574-020-0386-0"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2020.101152"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.4254\/wjh.v15.i6.755"},{"volume-title":"Cochrane Handbook for Systematic Reviews of Interventions Version 6.4 (Updated August 2023)","year":"2023","author":"Higgins J. P. T.","key":"e_1_2_9_17_1"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2009.06.006"},{"key":"e_1_2_9_19_1","first-page":"2","article-title":"RoB 2: A Revised Tool for Assessing Risk of Bias in Randomised Trials","volume":"366","author":"Sterne J. A. C.","year":"2019","journal-title":"British Medical Journal"},{"key":"e_1_2_9_20_1","unstructured":"GRADEpro GDT GRADEpro Guideline Development Tool [Software]McMaster University and Evidence Prime."},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2023.04.011"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2023.04.012"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)31785-9"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2016.09.001"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2010.04.054"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.12688\/f1000research.14117.1"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1080\/13543784.2020.1708898"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.2147\/TCRM.S352008"},{"key":"e_1_2_9_29_1","article-title":"Resmetirom, the First Drug Approved by the U.S. FDA for Treating Patients With Nonalcoholic Steatohepatitis","author":"Brett A. S.","year":"2024","journal-title":"NEJM Journal Watch"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/hepr.14020"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1111\/hepr.13993"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1002\/oby.22344"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1530\/eje.1.01821"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1530\/eje.0.1480293"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2016.05.013"},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.1111\/liv.14390"},{"key":"e_1_2_9_37_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0137302"},{"key":"e_1_2_9_38_1","doi-asserted-by":"publisher","DOI":"10.1152\/ajpgi.00283.2016"},{"key":"e_1_2_9_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(17)30582-2"},{"key":"e_1_2_9_40_1","doi-asserted-by":"publisher","DOI":"10.3390\/molecules26113316"},{"key":"e_1_2_9_41_1","unstructured":"\u201cBristol Myers Becomes Latest Victim of Unforgiving NASH as Midstage Asset Shelved | Fierce Biotech \u201d(2025) https:\/\/www.fiercebiotech.com\/biotech\/bristol\u2010myers\u2010becomes\u2010latest\u2010victim\u2010unforgiving\u2010nash\u2010as\u2010mid\u2010stage\u2010asset\u2010shelved."}],"container-title":["JGH Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jgh3.70131","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,29]],"date-time":"2025-03-29T05:52:04Z","timestamp":1743227524000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/jgh3.70131"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":40,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["10.1002\/jgh3.70131"],"URL":"https:\/\/doi.org\/10.1002\/jgh3.70131","archive":["Portico"],"relation":{},"ISSN":["2397-9070","2397-9070"],"issn-type":[{"type":"print","value":"2397-9070"},{"type":"electronic","value":"2397-9070"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"2024-07-08","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-03-02","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-03-17","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70131"}}